These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21317752)

  • 1. Excision repair cross-complementing-1 for small cell lung cancer.
    Kim YH; Ishii G; Ochiai A
    J Thorac Oncol; 2011 Mar; 6(3):652; author reply 652. PubMed ID: 21317752
    [No Abstract]   [Full Text] [Related]  

  • 2. ERCC1 and small cell lung cancer.
    Rossi G; Nannini N; Tiseo M
    J Thorac Oncol; 2010 Nov; 5(11):1876-7. PubMed ID: 20975385
    [No Abstract]   [Full Text] [Related]  

  • 3. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
    Chiappori AA; Zheng Z; Chen T; Rawal B; Schell MJ; Mullaney BP; Bepler G
    J Thorac Oncol; 2010 Apr; 5(4):484-90. PubMed ID: 20107425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
    Sereno M; Cejas P; Moreno V; Belda-Iniesta C; López R; Nistal M; Feliu J; De Castro Carpeño J
    Int J Oncol; 2012 Jun; 40(6):2104-10. PubMed ID: 22344449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation between expression of excision repair cross-complementing 1 and cisplatin sensitivity in non-small cell lung cancer].
    Han XP; Zhang X
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(30):2115-8. PubMed ID: 21029626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesothelioma and small cell lung cancer.
    Tsao AS; Heymach J
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1825-6. PubMed ID: 22005546
    [No Abstract]   [Full Text] [Related]  

  • 8. DNA repair by ERCC1 in non-small-cell lung cancer.
    Grenader T; Shavit L
    N Engl J Med; 2006 Dec; 355(24):2591; author reply 2591. PubMed ID: 17167936
    [No Abstract]   [Full Text] [Related]  

  • 9. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E; Rosell R
    Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair by ERCC1 in non-small-cell lung cancer.
    Wilcox JE
    N Engl J Med; 2006 Dec; 355(24):2590; author reply 2591. PubMed ID: 17171818
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS.
    Ceppi P; Papotti M; Scagliotti G
    Adv Med Sci; 2010; 55(1):22-5. PubMed ID: 20494871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
    Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin Analog Therapy in Small Cell Lung Cancer.
    Tartarone A; Lerose R; Aieta M
    Semin Nucl Med; 2016 May; 46(3):239-42. PubMed ID: 27067504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
    Bartolucci R; Wei J; Sanchez JJ; Perez-Roca L; Chaib I; Puma F; Farabi R; Mendez P; Roila F; Okamoto T; Taron M; Rosell R
    Clin Lung Cancer; 2009 Jan; 10(1):47-52. PubMed ID: 19289372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERCC1 measurements in clinical oncology.
    Reed E
    N Engl J Med; 2006 Sep; 355(10):1054-5. PubMed ID: 16957152
    [No Abstract]   [Full Text] [Related]  

  • 19. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.